[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.90.95. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
November 1979

Antinuclear Antibodies and Oral Methoxsalen Photochemotherapy (PUVA) for Psoriasis

Author Affiliations

From the Department of Dermatology, the Massachusetts General Hospital (Drs Stern, Morison, Parrish, and Fitzpatrick, and Ms Kleinerman); Beth Israel Hospital (Dr Stern); the Center for the Analysis of Health Practices, Harvard School of Public Health (Drs Stern and Thibodeau); and the Department of Computer Medicine, Beth Israel Hospital (Mr Geer), Harvard Medical School, Boston.

Arch Dermatol. 1979;115(11):1320-1324. doi:10.1001/archderm.1979.04010110026019
Abstract

In view of theoretical concern that psoralen ultraviolet A radiation (PUVA) therapy might induce a systemic lupus erythematosus-like syndrome, we studied serum antinuclear antibodies (ANAs) in patients with psoriasis who received PUVA and are participating in a five-year prospective study. At 14 centers, 1,023 patients had two or more ANA determinations. When first and last tests were compared, the incidence of positive tests for ANAs was not significantly different (P >.2). In addition, there was no apparent relationship between the frequency of PUVA treatments and the probability of a positive test. Over a two-year period, there is no evidence to indicate that PUVA therapy for psoriasis has resulted in a significantly higher number of positive tests for ANAs within our population.

(Arch Dermatol 115:1320-1324, 1979)

×